It is unknown how individuals with multiple sclerosis (MS) age compared to unaffected peers.
Objectives:
The objective of the study is to describe the impact of MS on health and functioning in aging women.
Methods:
We used 10-item Physical Functioning Scale (PF10) scores (from the Short Form-36 (SF-36)) and other indicators of general, physical, mental health, and memory collected repeatedly over 25 years with self-administered questionnaires among participants in the Nurses’ Health Study (n = 121,700 recruited at ages 30–55) and Nurses’ Health Study II (n = 116,429 recruited at ages 25–42) to compare women with MS (n = 733) to unaffected peers in their health and disability, and describe/quantify the burden of aging with MS.
Results:
Women with MS had a consistently lower PF10 by 0.9–1.7 standard deviations with greater overall variability than unaffected women. PF10-scores gradually decreased with increasing age in both groups, but MS cases declined 3–4 times faster in midlife, while decline was similar in old age. The physical function score of 45-year-old women with MS was comparable to that of 75-year-old unaffected women; 70-year-old women with MS scored similarly to 85-year-old unaffected women. MS cases also reported worse health/more disability throughout adulthood on the other indicators.
Conclusion:
The age-related decline in physical health is accelerated by 15–30 years in MS patients compared to unaffected peers.
LundeHMBAssmusJMyhrKM, et al. Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. J Neurol Neurosurg Psychiatry2017; 88(8): 621–625.
2.
Koch-HenriksenNLaursenBStenagerE, et al. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: A population based study. J Neurol Neurosurg Psychiatry2017; 88(8): 626–631.
3.
BollaertRESandroffBMStine-MorrowEAL, et al. The intersection of physical function, cognitive performance, aging, and multiple sclerosis: A cross-sectional comparative study. Cogn Behav Neurol2019; 32(1): 1–10.
4.
BollaertREBaltoJMSandroffBM, et al. Preliminary evidence for the effects of aging and multiple sclerosis on cognitive performance: An analysis based on effect size estimates. Exp Aging Res2017; 43(4): 346–354.
5.
MindenSLFrankelDHaddenLS, et al. Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. Neurorehabilitation2004; 19(1): 55–67.
6.
BuchananRJChakravortyBJTyryT, et al. Age-related comparisons of people with multiple sclerosis: Demographic, disease, and treatment characteristics. Neurorehabilitation2009; 25(4): 271–278.
7.
BrancoMRuanoLPortaccioE, et al. Aging with multiple sclerosis: Prevalence and profile of cognitive impairment. Neurol Sci2019; 40: 1651–1657.
8.
PittockSJMayrWTMcClellandRL, et al. Quality of life is favorable for most patients with multiple sclerosis: A population-based cohort study. Arch Neurol2004; 61(5): 679–686.
9.
RiaziAHobartJCLampingDL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson’s disease with normal population health profiles. J Neurol Neurosurg Psychiatry2003; 74(6): 710–714.
10.
KrokavcovaMvan DijkJPNagyovaI, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: A review. Scand J Caring Sci2009; 23(3): 529–538.
11.
SanaiSASainiVBenedictRH, et al. Aging and multiple sclerosis. Multiple Sclerosis2016; 22: 717–725.
12.
BaoYBertoiaMLLenartEB, et al. Origin, methods, and evolution of the three nurses’ health studies. Am J Public Health2016; 106(9): 1573–1581.
13.
HobartJFreemanJLampingD, et al. The SF-36 in multiple sclerosis: Why basic assumptions must be tested. J Neurol Neurosurg Psychiatry2001; 71(3): 363–370.
14.
PugliattiMRiiseTNortvedtMW, et al. Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients. J Neurol2008; 255(2): 157–162.
15.
FreemanJAHobartJCLangdonDW, et al. Clinical appropriateness: A key factor in outcome measure selection: The 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry2000; 68(2): 150–156.
16.
NortvedtMWRiiseTMyhrKM, et al. Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology1999; 53: 1098–1103.
17.
AmariglioRETownsendMKGrodsteinF, et al. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc2011; 59(9): 1612–1617.
18.
SamieriCProust-LimaCMMG, et al. Subjective cognitive concerns, episodic memory, and the APOE epsilon4 allele. Alzheimers Dement2014; 10: 752–759. e751.
19.
AmariglioREBuckleyRFMorminoEC, et al. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement2018; 4: 444–449.
20.
AmariglioREMorminoECPietrasAC, et al. Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly. Neurology2015; 85: 56–62.
21.
ScheefLSpottkeADaerrM, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology2012; 79: 1332–1339.
22.
van der FlierWMvan BuchemMAWeverling-RijnsburgerAW, et al. Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. J Neurol2004; 251(6): 671–675.
23.
GryttenNAarsethJHLundeHM, et al. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry2016; 87(1): 100–105.
24.
DentEMartinFCBergmanH, et al. Management of frailty: Opportunities, challenges, and future directions. Lancet2019; 394: 1376–1386.
25.
HoogendijkEOAfilaloJEnsrudKE, et al. Frailty: Implications for clinical practice and public health. Lancet2019; 394: 1365–1375.
26.
FrahmNHeckerMZettlUK.Polypharmacy among patients with multiple sclerosis: A qualitative systematic review. Expert Opin Drug Saf2020; 19(2): 139–145.
27.
LuWPikhartHSackerA.Domains and measurements of healthy aging in epidemiological studies: A review. Gerontologist2019; 59: e294–e310.
28.
RoySFrndakSDrakeAS, et al. Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Mult Scler2017; 23(10): 1385–1393.
29.
GrayVArnettP.Aging with multiple sclerosis: Cognitive, emotional and neuropathological considerations. Neurodegener Dis Manag2014; 4(2): 187–194.
30.
GhioneEBergslandNDwyerMG, et al. Aging and brain atrophy in multiple sclerosis. J Neuroimaging2019; 29(4): 527–535.
31.
VaughnCBJakimovskiDKavakKS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol2019; 15(6): 329–342.
32.
SchwehrNAKuntzKMButlerM, et al. Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Mult Scler2019; 26: 1510–1518.
33.
MarrieRACohenJStuveO, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler2015; 21(3): 263–281.
34.
CrielaardLKavaliunasARamanujamR, et al. Factors associated with and long-term outcome of benign multiple sclerosis: A nationwide cohort study. J Neurol Neurosurg Psychiatry2019; 90(7): 761–767.
35.
LerayECoustansMLe PageE, et al. ‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: Evidence from a 30-year observational study. Mult Scler2013; 19(4): 458–465.
36.
SayaoALDevonshireVTremlettH.Longitudinal follow-up of ‘benign’ multiple sclerosis at 20 years. Neurology2007; 68: 496–500.
37.
PloughmanMCollinsKWallackEM, et al. Women’s and men’s differing experiences of health, lifestyle, and aging with multiple sclerosis. Int J MS Care2017; 19(4): 165–171.
